| ISIN | CH0113817123 |
|---|---|
| Valor Number | 11381712 |
| Bloomberg Global ID | BBG0017T9CY3 |
| Fund Name | Bellevue Biotech DT CHF |
| Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
| Fund Provider | Bellevue Asset Management AG |
| Representative in Switzerland | |
| Distributor(s) |
Zürcher Kantonalbank Zürich Phone: +41 44 293 93 93 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Switzerland |
| Issuing Condition | Special conditions apply to the issue of units |
| Redemption Condition | Special conditions apply to the redemption of units |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 4,288.25 CHF | 06.01.2026 |
|---|---|---|
| Previous Price * | 4,188.79 CHF | 05.01.2026 |
| 52 Week High * | 4,426.67 CHF | 26.11.2025 |
| 52 Week Low * | 3,036.56 CHF | 10.04.2025 |
| NAV * | 4,288.25 CHF | 06.01.2026 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 20,936,970 | |
| Unit/Share Assets *** | 2,711,856 | |
| Trading Information SIX | ||
| YTD Performance | +1.43% |
31.12.2025 - 06.01.2026
31.12.2025 06.01.2026 |
|---|---|---|
| 1 month | -1.00% |
08.12.2025 - 06.01.2026
08.12.2025 06.01.2026 |
| 3 months | +10.31% |
06.10.2025 - 06.01.2026
06.10.2025 06.01.2026 |
| 6 months | +30.13% |
07.07.2025 - 06.01.2026
07.07.2025 06.01.2026 |
| 1 year | +17.77% |
06.01.2025 - 06.01.2026
06.01.2025 06.01.2026 |
| 2 years | +23.53% |
08.01.2024 - 06.01.2026
08.01.2024 06.01.2026 |
| 3 years | +14.74% |
06.01.2023 - 06.01.2026
06.01.2023 06.01.2026 |
| 5 years | +10.22% |
06.01.2021 - 06.01.2026
06.01.2021 06.01.2026 |
| Equity Participation Rate in % | 86.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | 16.6695 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | 06.01.2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amgen Inc | 7.89% | |
|---|---|---|
| Gilead Sciences Inc | 7.33% | |
| Vertex Pharmaceuticals Inc | 7.30% | |
| Regeneron Pharmaceuticals Inc | 6.22% | |
| Alnylam Pharmaceuticals Inc | 4.66% | |
| AstraZeneca PLC ADR | 4.46% | |
| Insmed Inc | 4.30% | |
| argenx SE ADR | 2.82% | |
| Biogen Inc | 2.32% | |
| BridgeBio Pharma Inc | 2.17% | |
| Last data update | 30.11.2025 | |
| TER | 1.22% |
|---|---|
| TER date | 30.09.2024 |
| Performance Fee *** | 10.00% |
| PTR | |
| Max. Management Fee *** | 1.50% |
| Ongoing Charges *** | |
|
SRRI ***
|
|
| SRRI date *** | 31.12.2025 |